Literature DB >> 28512229

Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations.

Pranesh Padmanabhan1, Narendra M Dixit2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28512229      PMCID： PMC5468610          DOI： 10.1073/pnas.1704531114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

1.  EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Authors:  Joachim Lupberger; Mirjam B Zeisel; Fei Xiao; Christine Thumann; Isabel Fofana; Laetitia Zona; Christopher Davis; Christopher J Mee; Marine Turek; Sebastian Gorke; Cathy Royer; Benoit Fischer; Muhammad N Zahid; Dimitri Lavillette; Judith Fresquet; François-Loïc Cosset; S Michael Rothenberg; Thomas Pietschmann; Arvind H Patel; Patrick Pessaux; Michel Doffoël; Wolfgang Raffelsberger; Olivier Poch; Jane A McKeating; Laurent Brino; Thomas F Baumert
Journal:  Nat Med       Date:  2011-04-24       Impact factor: 53.440

2.  Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry.

Authors:  Claire Bertaux; Tatjana Dragic
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.

Authors:  Andrew J Syder; Haekyung Lee; Mirjam B Zeisel; Joe Grove; Eric Soulier; James Macdonald; Stephine Chow; Julia Chang; Thomas F Baumert; Jane A McKeating; Jeffrey McKelvy; Flossie Wong-Staal
Journal:  J Hepatol       Date:  2010-08-21       Impact factor: 25.083

4.  A novel small molecule inhibitor of hepatitis C virus entry.

Authors:  Carl J Baldick; Michael J Wichroski; Annapurna Pendri; Ann W Walsh; Jie Fang; Charles E Mazzucco; Kevin A Pokornowski; Ronald E Rose; Betsy J Eggers; Mayla Hsu; Weixu Zhai; Guangzhi Zhai; Samuel W Gerritz; Michael A Poss; Nicholas A Meanwell; Mark I Cockett; Daniel J Tenney
Journal:  PLoS Pathog       Date:  2010-09-02       Impact factor: 6.823

5.  Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Authors:  Yoshiki Koizumi; Hirofumi Ohashi; Syo Nakajima; Yasuhito Tanaka; Takaji Wakita; Alan S Perelson; Shingo Iwami; Koichi Watashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

6.  Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.

Authors:  Rajiv G Tawar; Laura Heydmann; Charlotte Bach; Jörg Schüttrumpf; Shailesh Chavan; Barnabas J King; C Patrick McClure; Jonathan K Ball; Patrick Pessaux; François Habersetzer; Ralf Bartenschlager; Mirjam B Zeisel; Thomas F Baumert
Journal:  Hepatology       Date:  2016-09-30       Impact factor: 17.425

7.  A quantitative basis for antiretroviral therapy for HIV-1 infection.

Authors:  Benjamin L Jilek; Melissa Zarr; Maame E Sampah; S Alireza Rabi; Cynthia K Bullen; Jun Lai; Lin Shen; Robert F Siliciano
Journal:  Nat Med       Date:  2012-02-19       Impact factor: 53.440

8.  Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.

Authors:  Glen A Coburn; Danielle N Fisch; Sameer M Moorji; Jean-Marc de Muys; Jose D Murga; Dorothy Paul; Kathleen P Provoncha; Yakov Rotshteyn; Amy Q Han; Dapeng Qian; Paul J Maddon; William C Olson
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

9.  The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.

Authors:  François Helle; Anne Goffard; Virginie Morel; Gilles Duverlie; Jane McKeating; Zhen-Yong Keck; Steven Foung; François Penin; Jean Dubuisson; Cécile Voisset
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 10.  Hepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.

Authors:  Che C Colpitts; Thomas F Baumert
Journal:  Hepatol Int       Date:  2016-04-05       Impact factor: 9.029
  10 in total
  4 in total

1.  Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.

Authors:  Hirofumi Ohashi; Yoshiki Koizumi; Kento Fukano; Takaji Wakita; Alan S Perelson; Shingo Iwami; Koichi Watashi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-16       Impact factor: 11.205

Review 2.  Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.

Authors:  Rubesh Raja; Subhasish Baral; Narendra M Dixit
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

3.  Building a mechanistic mathematical model of hepatitis C virus entry.

Authors:  Mphatso Kalemera; Dilyana Mincheva; Joe Grove; Christopher J R Illingworth
Journal:  PLoS Comput Biol       Date:  2019-03-18       Impact factor: 4.475

4.  Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection.

Authors:  Vishnu Venugopal; Pranesh Padmanabhan; Rubesh Raja; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2018-07-12       Impact factor: 4.475
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.